Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josy Reiffers

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Haematologica|February 8, 2006
Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatmentMarie Colombat, Marie-Pierre Fort, Claudine Chollet, et al.
British Journal of Haematology|December 23, 2003
Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cellsMaria Mamani-Matsuda, Daniel Moynet, Mathieu Molimard, et al.
Blood|March 1, 2003
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line modelsFrançois-Xavier Mahon, Francis Belloc, Valérie Lagarde, et al.
Disease Markers|July 8, 2011
α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patientsGabriel Etienne, Maryse Dupouy, Patricia Costaglioli, et al.
Transfusion|January 10, 2006
A clinical-scale expansion of mobilized CD 34+ hematopoietic stem and progenitor cells by use of a new serum-free mediumZoran Ivanovic, Pascale Duchez, Bernard Dazey, et al.
Haematologica|November 21, 2007
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial resultsArnaud Pigneux, Virginie Perreau, Eric Jourdan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European surveyVanderson Rocha, Myriam Labopin, Eliane Gluckman, et al.
British Journal of Haematology|October 3, 2002
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571Christophe Barthe, Marie-Josée Gharbi, Valérie Lagarde, et al.
Cancer Biology & Therapy|March 22, 2007
Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteinsArnaud Pigneux, François-Xavier Mahon, François Moreau-Gaudry, et al.
American Journal of Hematology|September 19, 2012
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 studyPhilippe Rousselot, Pascale Cony-Makhoul, Franck Nicolini, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Haematologica|February 8, 2006
Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatmentMarie Colombat, Marie-Pierre Fort, Claudine Chollet, et al.
British Journal of Haematology|December 23, 2003
Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cellsMaria Mamani-Matsuda, Daniel Moynet, Mathieu Molimard, et al.
Blood|March 1, 2003
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line modelsFrançois-Xavier Mahon, Francis Belloc, Valérie Lagarde, et al.
Disease Markers|July 8, 2011
α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patientsGabriel Etienne, Maryse Dupouy, Patricia Costaglioli, et al.
Transfusion|January 10, 2006
A clinical-scale expansion of mobilized CD 34+ hematopoietic stem and progenitor cells by use of a new serum-free mediumZoran Ivanovic, Pascale Duchez, Bernard Dazey, et al.
Haematologica|November 21, 2007
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial resultsArnaud Pigneux, Virginie Perreau, Eric Jourdan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European surveyVanderson Rocha, Myriam Labopin, Eliane Gluckman, et al.
British Journal of Haematology|October 3, 2002
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571Christophe Barthe, Marie-Josée Gharbi, Valérie Lagarde, et al.
Cancer Biology & Therapy|March 22, 2007
Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteinsArnaud Pigneux, François-Xavier Mahon, François Moreau-Gaudry, et al.
American Journal of Hematology|September 19, 2012
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 studyPhilippe Rousselot, Pascale Cony-Makhoul, Franck Nicolini, et al.
Pageof 5